IBB
iShares Biotechnology ETF · Financial Services · Asset Management
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 83 | -2 | 30.99M | $5.89B | +5 | −7 |
| Q1 2026 | 86 | -2 | 32.07M | $5.40B | +4 | −6 |
| Q4 2025 | 87 | +2 | 31.81M | $5.28B | +2 | — |
| Q3 2025 | 12 | 0 | 8.03M | $1.16B | +2 | −2 |
| Q2 2025 | 9 | 0 | 315.48K | $39.91M | +2 | −2 |
| Q1 2025 | 7 | +1 | 400.58K | $51.23M | +2 | −1 |
| Q4 2024 | 6 | +1 | 526.12K | $69.56M | +2 | −1 |
| Q3 2024 | 5 | -2 | 433.42K | $63.11M | — | −2 |
| Q2 2024 | 7 | — | 747.92K | $102.66M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Two Sigma Investments ✦ | 423.41K | — | $58.12M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 217.69K | — | $29.88M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 65.30K | — | $8.96M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Marshall Wace ✦ | 18.09K | — | $2.48M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 17.14K | — | $2.35M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 3.61K | — | $497,000 | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Fisher Asset Management ✦ | 2.66K | — | $365,567 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 912 holders, 39.27M shares, $6.31B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.